Progress in 1q21 gain/amplification type multiple myeloma
10.3969/j.issn.1000-4718.2025.02.023
- VernacularTitle:伴1q21获得/扩增型多发性骨髓瘤的研究进展
- Author:
Jingbo SHI
1
;
Liming YU
;
Wei ZHENG
;
Siyuan CUI
Author Information
1. 山东中医药大学第一临床医学院,山东 济南 250014
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
karyotype;
chromosome 1q21
- From:
Chinese Journal of Pathophysiology
2025;41(2):394-402
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma(MM),a common malignancy of plasma cells,remains an incurable disease de-spite significant therapeutic advancements.A defining characteristic of MM is the recurrent occurrence of cytogenetic ab-normalities,particularly the gains of chromosome 1q21(1q21+),which are among the most frequently observed anoma-lies in this condition,affecting approximately 40%of patients with newly diagnosed MM.While numerous studies have identified 1q21+as an independent prognostic marker linked to poor outcomes in MM,its prognostic significance continues to be debated.An increasing number of national and international prognostic stratification systems classify 1q21+as a high-risk factor;however,its predictive value remains contentious.Variations in 1q21 copy numbers significantly impact genomic instability,drug resistance,and the likelihood of early disease progression,highlighting its growing importance in clinical management strategies.Despite the availability of various therapeutic approaches,such as autologous hemato-poietic stem cell transplantation,immunomodulatory drugs,and proteasome inhibitors,the adverse prognostic implica-tions of 1q21+persist unresolved.This review will explore the latest advancements in understanding the 1q21+in MM,fo-cusing on its pathogenesis,prognostic relevance,and implications for clinical management.
